Abstract
The systematic review of mesenchymal stromal cell (MSC) therapy in pulmonary fibrosis by Srour and Thébaud published in a recent issue of Stem Cells Translational Medicine is critically reviewed; Rubio et al. suggest that bleomycin-induced lung injury in aged mice studied over time is a more clinically applicable model for human idiopathic pulmonary fibrosis.